Contact us

S*BIO Initiates Canadian Phase 2 Clinical Trial of Oral Histone Deacetylase(HDAC) Inhibitor SB939

Share on facebook
Share on twitter
Share on linkedin
S*BIO Initiates Canadian Phase 2 Clinical Trial of Oral Histone Deacetylase (HDAC) Inhibitor SB939 for the Treatment of Recurrent or Metastatic Prostate Cancer (HRPC)
  • en
  • cn

    • English

    • English
    • Chinese

    © 2021- edbi. All rights reserved.